The large scale distribution of generic medicines benefits countries with fewer economic resources. They affirm that the States must carry out public policies that encourage the production and distribution of this type of medicines in a flexible way.
The European Union spent as much as 30% of GDP on social security and health during the pandemic. COVID-19 caused 500 million people to fall into extreme poverty by having to pay for medical services during the global crisis.
When it comes to medication, patients are often faced with choices between brand-name drugs and their generic counterparts. One important concept to understand in this decision-making process is bioequivalence.